Current understanding of metformin effect on the control of hyperglycemia in diabetes.

Metformin is a first-line oral anti-diabetic agent that has been used clinically to treat patients with type 2 diabetes for over 60 years. Due to its efficacy in therapy and affordable price, metformin is taken by more than 150 million people each year. Metformin improves hyperglycemia mainly through the suppression of hepatic gluconeogenesis along with the improvement of insulin signaling. However, its mechanism of action remains partially understood and controversial, especially in regard to the role of AMPK in metformin's action and the mechanism of AMPK activation. In this review, we discuss recent advances in the understanding of metformin's suppression of hepatic glucose production and the mechanism related to the improvement of insulin signaling.

[1]  Yong Jae Lee,et al.  Reciprocal Phosphorylation of Yeast Glycerol-3-Phosphate Dehydrogenases in Adaptation to Distinct Types of Stress , 2012, Molecular and Cellular Biology.

[2]  E. Mercken,et al.  Metformin improves healthspan and lifespan in mice , 2013, Nature Communications.

[3]  R. Heine,et al.  Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? , 2006, BMJ : British Medical Journal.

[4]  A. Hevener,et al.  IKK-beta links inflammation to obesity-induced insulin resistance. , 2005, Nature medicine.

[5]  G. Hollunger.  Guanidines and oxidative phosphorylations. , 2009, Acta pharmacologica et toxicologica.

[6]  F. Ovalle.  Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes: ZODIAC-16 , 2010 .

[7]  G Dailey,et al.  Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. , 1995, The New England journal of medicine.

[8]  M. Carlson,et al.  Mammalian TAK1 Activates Snf1 Protein Kinase in Yeast and Phosphorylates AMP-activated Protein Kinase in Vitro* , 2006, Journal of Biological Chemistry.

[9]  B. Kemp,et al.  AMPK Is a Direct Adenylate Charge-Regulated Protein Kinase , 2011, Science.

[10]  M. Rigoulet,et al.  Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I* , 2000, The Journal of Biological Chemistry.

[11]  Ian R. Holzman,et al.  Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. , 2009, The Journal of nutrition.

[12]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[13]  Kunihiro Suzuki,et al.  Metformin Inhibits Cytokine-Induced Nuclear Factor &kgr;B Activation Via AMP-Activated Protein Kinase Activation in Vascular Endothelial Cells , 2006, Hypertension.

[14]  Masahito Watanabe,et al.  IN MICE , 2009 .

[15]  M. Laville,et al.  Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. , 2011, The Journal of nutritional biochemistry.

[16]  R. Cole,et al.  Low Concentrations of Metformin Suppress Glucose Production in Hepatocytes through AMP-activated Protein Kinase (AMPK)*♦ , 2014, The Journal of Biological Chemistry.

[17]  T. Haystead,et al.  Purification of the AMP-activated protein kinase on ATP-gamma-sepharose and analysis of its subunit structure. , 1994, European journal of biochemistry.

[18]  A. Sim,et al.  The AMP-activated protein kinase: a multisubstrate regulator of lipid metabolism , 1989 .

[19]  M. Owen,et al.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.

[20]  F. Wondisford,et al.  Metformin Activates AMP-activated Protein Kinase by Promoting Formation of the αβγ Heterotrimeric Complex* , 2014, The Journal of Biological Chemistry.

[21]  David Carling,et al.  Structure of Mammalian AMPK and its regulation by ADP , 2011, Nature.

[22]  Juei-Tang Cheng,et al.  Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats. , 2006, Diabetes.

[23]  G. Rutter,et al.  Metformin activates a duodenal Ampk–dependent pathway to lower hepatic glucose production in rats , 2015, Nature Medicine.

[24]  T. Billiar,et al.  β2-Integrin-induced p38 MAPK Activation Is a Key Mediator in the CD14/TLR4/MD2-dependent Uptake of Lipopolysaccharide by Hepatocytes* , 2008, Journal of Biological Chemistry.

[25]  G. Shulman,et al.  Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. , 1998, The New England journal of medicine.

[26]  A. Thorburn,et al.  Mechanism of fat-induced hepatic gluconeogenesis: effect of metformin. , 2001, American journal of physiology. Endocrinology and metabolism.

[27]  B. Landau,et al.  Quantitative contributions of gluconeogenesis to glucose production during fasting in type 2 diabetes mellitus. , 2001, Metabolism: clinical and experimental.

[28]  A. Hevener,et al.  IKK-β links inflammation to obesity-induced insulin resistance , 2005, Nature Medicine.

[29]  Jeffrey I. Gordon,et al.  Mechanisms underlying the resistance to diet-induced obesity in germ-free mice , 2007, Proceedings of the National Academy of Sciences.

[30]  Michael J. MacDonald,et al.  Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase , 2014, Nature.

[31]  P. Light,et al.  Upper intestinal lipids trigger a gut–brain–liver axis to regulate glucose production , 2008, Nature.

[32]  E. Elamin,et al.  Short-chain fatty acids activate AMP-activated protein kinase and ameliorate ethanol-induced intestinal barrier dysfunction in Caco-2 cell monolayers. , 2013, The Journal of nutrition.

[33]  D. Cha,et al.  Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and Attenuates Renal Injury in db/db Mice , 2013, PloS one.

[34]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[35]  C. Watanabe.  STUDIES IN THE METABOLISM CHANGES INDUCED BY ADMINISTRATION OF GUANIDINE BASES I. INFLUENCE OF INJECTED GUANIDINE HYDROCHLORIDE UPON BLOOD SUGAR CONTENT , 1918 .

[36]  B. Viollet,et al.  Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP , 2016 .

[37]  B. Kemp,et al.  Mammalian AMP-activated Protein Kinase Subfamily (*) , 1996, The Journal of Biological Chemistry.

[38]  R. Sherwin,et al.  Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C. Watanabe.  STUDIES IN THE METABOLIC CHANGES INDUCED BY THE ADMINISTRATION OF GUANIDINE BASES:VI. The Influence of Guanidine Acidosis on the Fat Content of the Blood , 1922 .

[40]  Yao-jen Liang,et al.  Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. , 2009, International journal of cardiology.

[41]  E. Ropelle,et al.  Physical Exercise Reduces Circulating Lipopolysaccharide and TLR4 Activation and Improves Insulin Signaling in Tissues of DIO Rats , 2011, Diabetes.

[42]  J. H. Kim,et al.  Metformin sensitizes insulin signaling through AMPK‐mediated pten down‐regulation in preadipocyte 3T3‐L1 cells , 2011, Journal of cellular biochemistry.

[43]  M. Brown,et al.  Inactivation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in vitro. An adenine nucleotide-dependent reaction catalyzed by a factor in human fibroblasts. , 1975, The Journal of biological chemistry.

[44]  D. Hardie,et al.  AMP Is a True Physiological Regulator of AMP-Activated Protein Kinase by Both Allosteric Activation and Enhancing Net Phosphorylation , 2013, Cell metabolism.

[45]  D. Hardie,et al.  Role of the AMP-activated protein kinase in the cellular stress response , 1994, Current Biology.

[46]  Na-Ri Shin,et al.  An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice , 2013, Gut.

[47]  F. Ross,et al.  Use of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK Activation , 2010, Cell metabolism.

[48]  S. Inzucchi,et al.  Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.

[49]  R. Parakhia,et al.  Metformin Activates AMP Kinase through Inhibition of AMP Deaminase , 2010, The Journal of Biological Chemistry.

[50]  R. DePinho,et al.  The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin , 2005, Science.

[51]  J. Dyck,et al.  Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin–sensitizing effects of metformin , 2013, Nature Medicine.

[52]  F. Wondisford,et al.  Metformin and Insulin Suppress Hepatic Gluconeogenesis through Phosphorylation of CREB Binding Protein , 2009, Cell.

[53]  B. Kemp,et al.  Mammalian AMP-activated protein kinase shares structural and functional homology with the catalytic domain of yeast Snf1 protein kinase. , 1994, The Journal of biological chemistry.

[54]  F. Bäckhed,et al.  Obesity alters gut microbial ecology. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Jérôme Boudeau,et al.  LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR‐1 , 2004, The EMBO journal.

[56]  T. Haneji,et al.  Expression of PTEN and Akt phosphorylation in lipopolysaccharide‐treated NIH3T3 cells , 2007, Cell biology international.

[57]  K. Petersen,et al.  Mechanism by which metformin reduces glucose production in type 2 diabetes. , 2000, Diabetes.

[58]  R. Bibiloni,et al.  Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet–Induced Obesity and Diabetes in Mice , 2008, Diabetes.

[59]  C. Kahn,et al.  Insulin signalling and the regulation of glucose and lipid metabolism , 2001, Nature.

[60]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[61]  M. Kanaoka,et al.  Comparison of gene expression changes induced by biguanides in db/db mice liver. , 2008, The Journal of toxicological sciences.

[62]  J. Keaney,et al.  AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. , 2004, Biochemical and biophysical research communications.

[63]  S Kumar,et al.  Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. , 2007, American journal of physiology. Endocrinology and metabolism.

[64]  J. Cummings,et al.  Short chain fatty acids , 1994 .

[65]  A. Shehzad,et al.  Role of AMP‐Activated Protein Kinase in Cancer Therapy , 2014, Archiv der Pharmazie.

[66]  J. Clemente,et al.  Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice , 2013, Science.

[67]  J. Ferrières,et al.  Metabolic Endotoxemia Initiates Obesity and Insulin Resistance , 2007, Diabetes.

[68]  D. Hardie,et al.  AMPK: a nutrient and energy sensor that maintains energy homeostasis , 2012, Nature Reviews Molecular Cell Biology.

[69]  D. Carling,et al.  Mammalian AMP-activated protein kinase: functional, heterotrimeric complexes by co-expression of subunits in Escherichia coli. , 2003, Protein expression and purification.

[70]  Zhi-Xin Wang,et al.  Structural insight into the autoinhibition mechanism of AMP-activated protein kinase , 2009, Nature.

[71]  B. Viollet,et al.  Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. , 2010, The Journal of clinical investigation.

[72]  A. Edelman,et al.  Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. , 2005, Cell metabolism.

[73]  C. Bailey,et al.  Accumulation of metformin by tissues of the normal and diabetic mouse. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[74]  M. Wigler,et al.  The lipid phosphatase activity of PTEN is critical for its tumor supressor function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[75]  Eijiro Watanabe,et al.  Role of KLF 15 in regulation of hepatic gluconeogenesis and metformin action Running title : KLF 15 and metformin action , 2010 .

[76]  Qing He,et al.  Inactivation of NF-κB p50 Leads to Insulin Sensitization in Liver through Post-translational Inhibition of p70S6K* , 2009, The Journal of Biological Chemistry.

[77]  R. Shulman,et al.  Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. , 1992, The Journal of clinical investigation.

[78]  F. Wondisford,et al.  Metformin action: concentrations matter. , 2015, Cell metabolism.